论文部分内容阅读
目的:探讨肾透明细胞癌胰腺转移患者的临床特征和预后。方法:回顾性分析2000年1月至2020年5月间天津医科大学肿瘤医院收治的20例经病理确诊的肾透明细胞癌胰腺转移患者的临床资料，记录患者的性别、年龄、转移时间、复发时间、转移部位、胰腺转移灶数目及对于胰腺转移灶是否进行手术等，分析其预后影响因素。结果:20例患者中男性12例，女性8例；确诊肾透明细胞癌的中位年龄为50岁。其中肾癌位于左肾12例(60%)，右肾8例(40%)；胰腺转移癌单发病灶12例(60%)，多发病灶8例(40%)；仅转移至胰腺13例(65%)，合并其他部位转移7例(35%)；肾癌和胰腺转移癌同时发现(同时性转移)2例(10%)，肾癌确诊后发生胰腺转移18例(90%)。确诊肾透明细胞癌至发生胰腺转移的中位时间为102个月。10年内胰腺复发13例(65%)，10年后复发7例(35%)。胰腺转移癌手术切除9例，靶向治疗13例。随访时间为1～256个月，平均随访时间122.9个月。死亡3例(15%)，生存17例(85%)，中位生存时间为75.9个月，5年生存率为66.7%。是否为同时性转移、是否合并胰腺外转移是影响肾透明细胞癌胰腺转移患者的预后因素。结论:肾透明细胞癌胰腺转移较为罕见，但预后较好，尤其是确诊肾癌数年后仅发生胰腺转移的患者。“,”Objective:To investigate the clinical features and prognosis of patients with pancreatic metastasis from clear cell renal cell carcinoma(CCRCC).Methods:From Jan 2000 to May 2020, the clinical data of patients pathologically diagnosed as CCRCC with pancreatic metastasis and admitted in Cancer Institute and Hospital of Tianjin Medical University were analyzed retrospectively. The gender, age, metastasis time, relapse time, metastatic sites, numbers of metastatic lesions and whether metastatic pancreatic lesions should be surgerically removed were recorded and the influencing factors were analyzed.Results:Among the 20 patients, there were 12 males and 8 females. The median age of diagnosis was 50 years. There were 12 patients(60%) of left renal carcinoma and 8 patients(40%)of the other side. 12 cases(60%) had single pancreatic metastatic lesion and the other 8 cases(40%) had multiple metastatic lesions. Seven patients(35%) had other organs metastasis besides pancreatic metastasis. Two patients(10%) had simultaneous pancreatic metastasis and renal cancer, and the other eighteen patients(90%) had pancreatic metachronous metastasis after being diagnosed as renal cancer. The median time from the diagnosis of CCRCC to pancreatic metastasis was 102 months. Thirteen patients(65%)had recurrences within 10 years and the other seven patients(35%)had recurrences after 10 years. Pancreatectomy was performed in nine patients(45%) and targeted therapy was conducted in thirteen patients. The mean follow-up was 122.9 months (1-256 months). Three patients (15%) died and 17 patients (85%) survived. The median overall survival was 75.9 months, and the 5 year-survival rate was 66.7%. Simultaneous metastasis and extra-pancreatic metastasis were prognostic factors in patients with CCRCC with pancreatic metastasis.Conclusions:Pancreatic metastases from renal clear cell carcinoma were rare, but the prognosis was good, especially in patients with only pancreatic metastases several years after renal carcinoma was diagnosed.